TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3,3',4,4'-Tetrachloroazobenzene **CAS Number:** 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

Species/Strain: MICE/B6C3F1

F_2_M3

C Number: C88148C

Lock Date: 08/31/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

TDMSE Version: 2.1.0

Test Type: CHRONIC3,3',4,4'-TetrachloroazobenzeneRoute: GAVAGECAS Number: 14047-09-7

Species/Strain: MICE/B6C3F1

TDMS No. 88148 - 07

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
isposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths	00	00	00	00
Accidently Killed			1	
Dosing Accident	1		1	40
Moribund Sacrifice Natural Death	10 4	11 8	16 26	19 31
Survivors	4	0	20	31
Terminal Sacrifice	35	31	5	
Missing	33	٥.	1	
Animals Examined Microscopically	50	50	49	50
LIMENTARY SYSTEM				
Esophagus	(50)	(50)	(49)	(50)
Perforation	1 (2%)			
Epithelium, Necrosis	1 (2%)			
Periesophageal Tissue, Inflammation, Chronic Active	1 (2%)			
Gallbladder	(49)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	2 (4%)	(50)	(49)	(30)
Inflammation, Chronic Active	1 (2%)			
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Cyst	,	,	1 (2%)	, ,
Intestine Large, Rectum	(50)	(50)	(49)	(50)
Intestine Small, Duodenum	(50)	(50)	(49)	(50)
Intussusception	(50)	1 (2%)	(40)	(FC)
Intestine Small, Ileum Intestine Small, Jejunum	(50) (50)	(50) (50)	(49) (49)	(50) (50)
Liver	(50)	(50)	(49) (49)	(50)
Amyloid Deposition	(30)	3 (6%)	2 (4%)	(30)
Atypia Cellular		1 (2%)	= (:/3)	
Basophilic Focus		4 (8%)	2 (4%)	2 (4%)
Clear Cell Focus	12 (24%)	6 (Ì2%́)	1 (2%)	` ,
Congestion			1 (2%)	1 (2%)
Eosinophilic Focus	5 (10%)	1 (2%)	3 (6%)	0 (001)
Hematopoietic Cell Proliferation	2 (4%)	9 (18%)	9 (18%)	3 (6%)
Hemorrhage Infarct	1 (2%) 1 (2%)	1 (20/)	1 (2%)	
Infaltration Cellular, Lymphoid	7 (2%)	1 (2%) 16 (32%)	11 (22%)	2 (4%)
Inflammation, Chronic Active	35 (70%)	32 (64%)	17 (35%)	14 (28%)
Mineralization	1 (2%)	1 (2%)	(5575)	1. (2070)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Mixed Cell Focus	4 (8%)	6 (12%)		2 (49/)	
Pigmentation	2 (4%)	1 (2%)		2 (4%)	
Tension Lipidosis	2 (4%)	5 (10%)	12 (24%)	15 (30%)	
Thrombosis	1 (2%)	3 (10%)	12 (24 /0)	13 (30 %)	
Bile Duct, Hyperplasia	1 (2%)				
		4 (90/)	2 (40/)		
Hepatocyte, Necrosis	5 (10%) 31 (62%)	4 (8%)	2 (4%)	11 (220/)	
Hepatocyte, Vacuolization Cytoplasmic		31 (62%)	23 (47%)	11 (22%)	
lesentery	(5)	(5)	(4)	(2)	
Fat, Fibrosis	4 (80%)	2 (40%)	0 (750)	4 (500()	
Fat, Inflammation, Chronic Active	3 (60%)	5 (100%)	3 (75%)	1 (50%)	
Fat, Mineralization	1 (20%)	2 (40%)	4 (050()		
Fat, Necrosis	4 (80%)	3 (60%)	1 (25%)	(0)	
ral Mucosa	(0)	(1)	(0)	(0)	
Gingival, Inflammation, Chronic Active	(50)	1 (100%)	(40)	(50)	
ancreas	(50)	(50)	(49)	(50)	
Infiltration Cellular, Lymphoid	6 (12%)	5 (10%)	1 (2%)	4 (00()	
Inflammation, Chronic Active	4 (00()	2 (4%)	1 (2%)	1 (2%)	
Duct, Cyst	1 (2%)	(50)	(40)	(50)	
alivary Glands	(50)	(50)	(49)	(50)	
Degeneration	1 (2%)	24 (2224)	22 (472)	. (00/)	
Infiltration Cellular, Lymphoid	43 (86%)	34 (68%)	22 (45%)	4 (8%)	
Mineralization	(==)	(==)	1 (2%)	(=0)	
tomach, Forestomach	(50)	(50)	(49)	(50)	
Infiltration Cellular, Lymphoid			1 (2%)	- 4	
Inflammation, Chronic Active	6 (12%)	7 (14%)	6 (12%)	3 (6%)	
Epithelium, Cyst	1 (2%)				
Epithelium, Hyperplasia	8 (16%)	21 (42%)	33 (67%)	44 (88%)	
Epithelium, Ulcer	5 (10%)	3 (6%)	3 (6%)	2 (4%)	
tomach, Glandular	(50)	(50)	(49)	(50)	
Infiltration Cellular, Lymphoid	3 (6%)	20 (40%)	19 (39%)	15 (30%)	
Infiltration Cellular, Mast Cell		1 (2%)			
Inflammation, Chronic Active		1 (2%)	1 (2%)	1 (2%)	
Mineralization		4 (8%)	6 (12%)	13 (26%)	
Epithelium, Hyperplasia	1 (2%)				
Epithelium, Hyperplasia, Focal		10 (20%)	20 (41%)	34 (68%)	
Epithelium, Ulcer			1 (2%)		
Epithelium, Glands, Cyst	5 (10%)	18 (36%)	21 (43%)	26 (52%)	
Glands, Cyst			1 (2%)	1 (2%)	
ongue	(0)	(1)	(0)	(0)	
Cyst, Multiple		1 (100%)			
Artery, Inflammation, Chronic Active		1 (100%)			
ooth	(8)	(3)	(0)	(0)	
Dysplasia	3 (38%)				
Malformation	4 (50%)	3 (100%)			

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(49)	(50)	
Hyperplasia Aorta, Inflammation, Chronic Active	1 (2%)	2 (40/)			
Aorta, Mineralization		2 (4%)	6 (12%)	8 (16%)	
Heart	(50)	(50)	(49)	(50)	
Cardiomyopathy	5 (10%)	5 (10%)	17 (35%)	9 (18%)	
Hyperplasia, Atypical		2 (4%)			
Infiltration Cellular, Lymphoid	1 (2%)	((001)	2 (124)	. (00()	
Inflammation, Chronic Active Mineralization	1 (2%)	1 (2%)	2 (4%)	1 (2%) 1 (2%)	
Necrosis		2 (4%)		3 (6%)	
Artery, Hyperplasia	1 (2%)			3 (070)	
Artery, Inflammation, Chronic Active	2 (4%)	2 (4%)			
Myocardium, Necrosis		1 (2%)			
NDOCRINE SYSTEM					
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation	(50)	(50) 2 (4%)	(49) 4 (8%) 1 (2%) 1 (2%)	(50)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia	1 (2%)	2 (4%)	4 (8%) 1 (2%) 1 (2%)	(50)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy			4 (8%) 1 (2%)		
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule	1 (2%) 9 (18%)	2 (4%) 5 (10%)	4 (8%) 1 (2%) 1 (2%) 1 (2%)	1 (2%)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic	1 (2%) 9 (18%) 45 (90%) (50)	2 (4%) 5 (10%) 38 (76%) (50)	4 (8%) 1 (2%) 1 (2%)		
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49)	1 (2%) 27 (54%) (50)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45)	2 (4%) 5 (10%) 38 (76%) (50)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%)	1 (2%) 27 (54%)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49)	1 (2%) 27 (54%) (50)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst Cyst, Multiple	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45) 1 (2%)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47) 1 (2%)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49)	1 (2%) 27 (54%) (50) (44)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst Cyst, Multiple Pituitary Gland	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49)	1 (2%) 27 (54%) (50) (44)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst Cyst, Multiple Pituitary Gland Pars Distalis, Cyst Pars Distalis, Cyst, Multiple	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45) 1 (2%) (49) 2 (4%) 1 (2%)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47) 1 (2%) (50) 4 (8%)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49) (46) (48) 1 (2%)	1 (2%) 27 (54%) (50) (44) (50) 3 (6%) 1 (2%)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst Cyst, Multiple Pituitary Gland Pars Distalis, Cyst Pars Distalis, Cyst, Multiple Thyroid Gland	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45) 1 (2%) (49) 2 (4%) 1 (2%) (50)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47) 1 (2%) (50)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49) (46)	1 (2%) 27 (54%) (50) (44) (50) 3 (6%)	
Adrenal Cortex Accessory Adrenal Cortical Nodule Amyloid Deposition Hematopoietic Cell Proliferation Hyperplasia Hypertrophy Bilateral, Accessory Adrenal Cortical Nodule Subcapsular, Hyperplasia Islets, Pancreatic Hyperplasia Parathyroid Gland Cyst Cyst, Multiple Pituitary Gland Pars Distalis, Cyst Pars Distalis, Cyst, Multiple	1 (2%) 9 (18%) 45 (90%) (50) 5 (10%) (45) 1 (2%) (49) 2 (4%) 1 (2%)	2 (4%) 5 (10%) 38 (76%) (50) 3 (6%) (47) 1 (2%) (50) 4 (8%)	4 (8%) 1 (2%) 1 (2%) 1 (2%) 37 (76%) (49) (46) (48) 1 (2%)	1 (2%) 27 (54%) (50) (44) (50) 3 (6%) 1 (2%)	

GENERAL BODY SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07
Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene
CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
GENITAL SYSTEM					
Coagulating Gland	(50)	(50)	(49)	(50)	
Atrophy	1 (2%)	(0.4004)	(=0.01)	(= (a (a())	
Dilatation	9 (18%)	16 (32%)	36 (73%)	47 (94%)	
Fibrosis	- 4	6 (12%)	23 (47%)	30 (60%)	
Infiltration Cellular, Lymphoid	3 (6%)	6 (12%)	2 (4%)		
Inflammation, Chronic Active		6 (12%)	22 (45%)	33 (66%)	
Epithelium, Hyperplasia	1 (2%)	1 (2%)	5 (10%)	1 (2%)	
Ductus Deferens	(50)	(50)	(49)	(50)	
Inflammation, Chronic Active			3 (6%)		
Epididymis	(50)	(50)	(49)	(50)	
Atrophy	1 (2%)				
Cyst		1 (2%)	1 (2%)		
Granuloma Sperm	1 (2%)	3 (6%)	6 (12%)	8 (16%)	
Infiltration Cellular, Lymphoid	40 (80%)	30 (60%)	21 (43%)	15 (30%)	
Inflammation, Chronic Active	,	3 (6%)	2 (4%)	,	
Preputial Gland	(50)	(50)	(49)	(50)	
Atrophy	20 (40%)	23 (46%)	24 (49%)	9 (18%)	
Infiltration Cellular, Lymphoid	18 (36%)	3 (6%)	_ : (: 5 , 5)	- (1-7-7)	
Inflammation, Chronic Active	10 (0070)	7 (14%)	3 (6%)	2 (4%)	
Duct, Ectasia	19 (38%)	15 (30%)	23 (47%)	10 (20%)	
Prostate	(50)	(50)	(49)	(50)	
Fibrosis	(30)	1 (2%)	3 (6%)	1 (2%)	
Infiltration Cellular, Lymphoid	42 (84%)	43 (86%)	26 (53%)	9 (18%)	
Inflammation, Chronic Active	3 (6%)	10 (20%)	27 (55%)	44 (88%)	
Mineralization	1 (2%)	10 (20%)	27 (3376)	44 (0070)	
Artery, Hyperplasia	1 (2%)				
Artery, Tryperplasia Artery, Inflammation, Chronic Active	1 (2%)				
Epithelium, Hyperplasia	4 (8%)		1 (2%)		
Seminal Vesicle		(50)		(50)	
	(50)	(50)	(49)	(50)	
Atrophy	1 (2%)	4.4 (200()	20 (700()	44 (000/)	
Dilatation	12 (24%)	14 (28%)	38 (78%)	41 (82%)	
Fibrosis		3 (6%)	18 (37%)	29 (58%)	
Inflammation, Chronic Active		4 (8%)	14 (29%)	22 (44%)	
Epithelium, Hyperplasia	(50)	1 (2%)	5 (10%)	1 (2%)	
Testes	(50)	(50)	(49)	(50)	
Mineralization	1 (2%)	1 (2%)	3 (6%)	2 (4%)	
Germinal Epithelium, Degeneration	8 (16%)	1 (2%)	3 (6%)	3 (6%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(49)	(50)	
Dono Mariow	(30)	(50)	(+3)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Hyperplasia Myelofibrosis	13 (26%)	10 (20%)	17 (35%) 1 (2%)	20 (40%)	
Erythroid Cell, Hyperplasia	1 (2%)		(/		
_ymph Node	(2)	(1)	(2)	(0)	
Mediastinal, Hyperplasia, Lymphoid	()	()	1 (ŠÓ%)	()	
_ymph Node, Mandibular	(49)	(50)	(48)	(49)	
Hematopoietic Cell Proliferation			1 (2%)		
Hyperplasia, Lymphoid	3 (6%)	7 (14%)	7 (15%)		
Hyperplasia, Plasma Cell		2 (4%)	1 (2%)		
Necrosis, Lymphoid			1 (2%)		
Lymph Node, Mesenteric	(50)	(49)	(48)	(50)	
Hyperplasia, Lymphoid	1 (2%)	4	1 (2%)	4.5	
Spleen	(50)	(50)	(49)	(49)	
Amyloid Deposition	0 (40()	4 (8%)	2 (4%)	00 (000()	
Atrophy	2 (4%)	9 (18%)	30 (61%)	39 (80%)	
Hematopoietic Cell Proliferation Artery, Hyperplasia	18 (36%) 1 (2%)	16 (32%)	12 (24%)	7 (14%)	
Artery, Inflammation, Chronic Active	1 (2%)				
Lymphoid Follicle, Necrosis, Lymphoid	1 (270)		1 (2%)		
Chymus	(41)	(42)	(40)	(49)	
Atrophy	11 (27%)	15 (36%)	30 (75%)	45 (92%)	
Cyst	5 (12%)	2 (5%)	5 (13%)	5 (10%)	
Cyst, Multiple	19 (46%)	28 (67%)	27 (68%)	35 (71%)	
Ectopic Parathyroid Gland	8 (20%)	8 (19%)	3 (8%)	9 (18%)	
Inflammation, Chronic Active	(==75)	C (1070)	1 (3%)	(() () ()	
Thymocyte, Necrosis			2 (5%)	3 (6%)	
EGUMENTARY SYSTEM					
Skin	(50)	(50)	(49)	(50)	
Cyst Epithelial Inclusion Hemorrhage		1 (2%)	1 (2%)		
Inflammation, Acute			1 (2/0)	1 (2%)	
Inflammation, Chronic Active	3 (6%)	13 (26%)	12 (24%)	5 (10%)	
Dermis, Fibrosis	3 (6%)	12 (24%)	12 (24%)	4 (8%)	
Dermis, Metaplasia, Osseous	5 (575)	1 (2%)	(=)	. (575)	
Epidermis, Hyperkeratosis		1 (2%)			
Epidermis, Hyperplasia	3 (6%)	13 (26%)	12 (24%)	6 (12%)	
Epidermis, Ulcer	3 (6%)	13 (26%)	11 (22%)	6 (12%)	
Hair Follicle, Dilatation	7 (14%)	10 (20%)	13 (27%)	28 (56%)	
Sebaceous Gland, Atrophy	13 (26%)	10 (20%)	20 (41%)	29 (58%)	
Subcutaneous Tissue, Inflammation, Chronic	, ,	, ,	, ,	1 (2%)	
Active				` '	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene **CAS Number:** 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
MUSCULOSKELETAL SYSTEM				
Bone Osteopetrosis	(50)	(50) 2 (4%)	(49) 1 (2%)	(50)
Skeletal Muscle	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid Inflammation, Chronic Active	2 (4%)	1 (2%)		
NERVOUS SYSTEM				
Brain Degeneration	(50)	(50) 1 (2%)	(49)	(50)
Inflammation, Chronic Active	1 (2%)	. (270)	4 (00)	
Neuron, Necrosis			1 (2%)	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Congestion Fibrosis		1 (2%)	1 (2%) 1 (2%)	
Infiltration Cellular, Lymphoid		4 (8%)		4 (00()
Inflammation, Chronic Active Alveolar Epithelium, Hyperplasia	5 (10%)	2 (4%) 6 (12%)	1 (2%) 2 (4%)	1 (2%) 2 (4%)
Alveolus, Infiltration Cellular, Histiocyte	4 (8%)	6 (12%)	1 (2%)	£ (±70)
Mediastinum, Inflammation, Chronic Active		1 (2%)		(=c)
Nose Hemorrhage	(50)	(50)	(49) 1 (2%)	(50)
Inflammation, Chronic Active			1 (2%)	
Nasolacrimal Duct, Inflammation, Chronic Active	1 (2%)		. (270)	
Nasolacrimal Duct, Squamous Epithelium, Hyperplasia	2 (4%)			
Pleura	(1)	(1)	(1)	(0)
Trachea Enithelium Mineralization	(50)	(50)	(49)	(50) 1 (2%)
Epithelium, Mineralization				1 (2%)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(49)	(50)
Atrophy Anterior Chamber, Cornea, Inflammation,	1 (2%)		1 (2%)	2 (4%)
Suppurative Cornea, Inflammation, Chronic Active	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Cornea, Pigmentation		4 (00()	1 (2%)		
Optic Nerve, Inflammation, Chronic Active Harderian Gland	(50)	1 (2%)	(40)	(50)	
Degeneration	(50)	(50)	(49)	(50) 1 (2%)	
Hyperplasia	3 (6%)	2 (4%)	1 (2%)	1 (270)	
Infiltration Cellular, Lymphoid	33 (66%)	26 (52%)	7 (14%)	1 (2%)	
Inflammation, Chronic Active		1 (2%)			
Necrosis			1 (2%)		
JRINARY SYSTEM					
Kidney	(50)	(50)	(49)	(50)	
Hydronephrosis	1 (2%)	5 (10%)	17 (35%)	29 (58%)	
Infarct	4 (8%)		1 (2%)		
Infiltration Cellular, Lymphoid	39 (78%)	38 (76%)	12 (24%)	3 (6%)	
Inflammation, Acute Inflammation, Chronic Active			5 (10%)	3 (6%) 2 (4%)	
Metaplasia, Osseous	2 (4%)	3 (6%)	1 (2%)	1 (2%)	
Mineralization	40 (80%)	43 (86%)	40 (82%)	42 (84%)	
Nephropathy	47 (94%)	45 (90%)	28 (57%)	24 (48%)	
Thrombosis	47 (0470)	40 (0070)	20 (07 70)	4 (8%)	
Artery, Inflammation, Chronic Active	2 (4%)	1 (2%)		(2,75)	
Cortex, Cyst	11 (22%)	6 (12%)	2 (4%)		
Cortex, Cyst, Multiple	` '	,	1 (2%)		
Glomerulus, Amyloid Deposition		6 (12%)	4 (8%)	1 (2%)	
Papilla, Necrosis		3 (6%)	3 (6%)		
Pelvis, Hyperplasia	1 (2%)			1 (2%)	
Renal Tubule, Dilatation	1 (2%)	8 (16%)	31 (63%)	43 (86%)	
Renal Tubule, Hyperplasia	1 (2%)				
Ureter	(43)	(45)	(47)	(50)	
Dilatation		6 (13%)	22 (47%)	42 (84%)	
Inflammation, Chronic Active	(40)	3 (7%)	24 (51%)	39 (78%)	
Urethra	(48)	(50)	(49)	(50)	
Dilatation	1 (20/)	1 (2%)	2 (4%)	2 (4%)	
Inflammation, Chronic Active Artery, Hyperplasia	1 (2%) 1 (2%)		1 (2%)		
Artery, Inflammation, Chronic Active	1 (2%)				
Transitional Epithelium, Hyperplasia	1 (2/0)	17 (34%)	2 (4%)		
Transitional Epithelium, Inflammation, Chronic		1 (2%)	£ (470)		
Active		· (2/0)			
Urinary Bladder	(50)	(50)	(49)	(50)	
Infiltration Cellular, Lymphoid	25 (50%)	25 (50%)	4 (8%)	(55)	
Inflammation, Chronic Active	_0 (0070)	1 (2%)	1 (2%)	2 (4%)	
Transitional Epithelium, Hyperplasia		1 (2%)	. (=,-,	4 (8%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 **Test Type:** CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG

*** END OF MALE ***

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

isposition Summary Animals Initially in Study					
Animals Initially in Study					
	50	50	50	50	
Early Deaths	_				
Dosing Accident Moribund Sacrifice	1	0	1	1	
Natural Death	6 8	9 11	9 8	21 8	
Survivors	8	11	O	0	
Natural Death				1	
Terminal Sacrifice	35	30	32	19	
Animals Examined Microscopically	50	50	50	50	
LIMENTARY SYSTEM					
Esophagus	(49)	(50)	(50)	(50)	
Perforation	1 (2%)	(00)	1 (2%)	1 (2%)	
Gallbladder	(49)	(50)	(50)	(50)	
Infiltration Cellular, Lymphoid	3 (6%)	3 (6%)	2 (4%)	1 (2%)	
Inflammation, Chronic Active	,	` ,	1 (2%)	, ,	
Intestine Large, Cecum	(49)	(50)	(49)	(50)	
Inflammation, Chronic Active		1 (2%)			
Ulcer		1 (2%)			
Intestine Large, Colon	(49)	(50)	(49)	(50)	
Intestine Large, Rectum	(49)	(50)	(50)	(50)	
Inflammation, Chronic Active	1 (2%)	(50)	(50)	(50)	
Intestine Small, Duodenum	(49)	(50) (50)	(50) (50)	(50) (50)	
Intestine Small, Jejunum Peyer's Patch, Hyperplasia, Lymphoid	(49)	(50)	(50) 1 (2%)	3 (6%)	
Liver	(49)	(50)	(50)	(50)	
Amyloid Deposition	(40)	(50)	2 (4%)	4 (8%)	
Basophilic Focus	1 (2%)	6 (12%)	3 (6%)	1 (2%)	
Clear Cell Focus	2 (4%)	1 (2%)	1 (2%)	- (= / = /	
Eosinophilic Focus	2 (4%)	\/	1 (2%)	1 (2%)	
Hematopoietic Cell Proliferation	3 (6%)	9 (18%)	9 (18%)	21 (42%)	
Infarct				3 (6%)	
Infiltration Cellular, Histiocyte				1 (2%)	
Infiltration Cellular, Lymphoid	38 (78%)	40 (80%)	38 (76%)	28 (56%)	
Inflammation, Chronic Active	39 (80%)	37 (74%)	37 (74%)	32 (64%)	
Mineralization	0 (00()	1 (2%)	4 (00()	1 (2%)	
Mixed Cell Focus	3 (6%)	3 (6%)	4 (8%)	1 (2%)	
Tension Lipidosis	4 (8%)	6 (12%)	4 (8%)	4 (8%)	
Bile Duct, Hyperplasia Bile Duct, Inflammation, Chronic Active		1 (2%)		2 (4%) 1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

3,3',4,4'-Tetrachloroazobenzene

CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Hepatocyte, Necrosis	1 (2%)	1 (2%)	3 (6%)	3 (6%)	
Hepatocyte, Vacuolization Cytoplasmic	33 (67%)	33 (66%)	35 (70%)	20 (40%)	
Mesentery	(5)	(12)	(9)	(15)	
Congestion	(5)	(12)	1 (11%)	(13)	
Fat, Cyst	1 (20%)		1 (1170)		
Fat, Fibrosis	3 (60%)	6 (50%)	5 (56%)	6 (40%)	
Fat, Inflammation, Chronic Active	2 (40%)	6 (50%)	4 (44%)	7 (47%)	
Fat, Mineralization	2 (40%)	1 (8%)	3 (33%)	7 (47%)	
Fat, Necrosis	2 (600/)	5 (42%)	5 (56%) 5 (56%)	0 (530/)	
	3 (60%)	5 (42%)		8 (53%)	
Pancreas	(49)	(50)	(50)	(50)	
Basophilic Focus	1 (2%)			4 (00()	
Congestion		_ /		1 (2%)	
Infiltration Cellular, Lymphoid	12 (24%)	5 (10%)	6 (12%)	3 (6%)	
Inflammation, Chronic Active			2 (4%)	1 (2%)	
Mineralization				1 (2%)	
Acinus, Atrophy		1 (2%)			
Duct, Cyst		1 (2%)			
Duct, Cyst, Multiple				1 (2%)	
Salivary Glands	(49)	(50)	(50)	(50)	
Infiltration Cellular, Lymphoid	36 (73%)	23 (46%)	13 (26%)	1 (2%)	
Mineralization	,	1 (2%)	,	,	
Stomach, Forestomach	(49)	(50)	(50)	(50)	
Infiltration Cellular, Lymphoid	2 (4%)	(33)	2 (4%)	10 (20%)	
Inflammation, Chronic Active	1 (2%)	4 (8%)	1 (2%)	1 (2%)	
Mineralization	1 (270)	4 (070)	1 (270)	1 (2%)	
Epithelium, Cyst		1 (2%)	2 (4%)	1 (270)	
Epithelium, Hyperplasia	8 (16%)	27 (54%)	38 (76%)	43 (86%)	
Epithelium, Ulcer	1 (2%)	3 (6%)	1 (2%)	43 (00%)	
Stomach, Glandular	(49)	(50)		(50)	
	(49)		(50)	(50)	
Infiltration Cellular, Lymphoid	1 (2%)	14 (28%)	30 (60%)	28 (56%)	
Infiltration Cellular, Mast Cell	1 (2%)		4 (00()	4 (00()	
Inflammation, Chronic Active	2 (4%)	4 (00()	1 (2%)	1 (2%)	
Mineralization	1 (2%)	4 (8%)	3 (6%)	3 (6%)	
Epithelium, Erosion		1 (2%)	()	/	
Epithelium, Hyperplasia, Focal	1 (2%)	19 (38%)	26 (52%)	28 (56%)	
Epithelium, Necrosis			1 (2%)		
Epithelium, Ulcer		1 (2%)		1 (2%)	
Epithelium, Glands, Cyst	8 (16%)	19 (38%)	13 (26%)	22 (44%)	
Tongue	(0)	(1)	(0)	(1)	
Tooth	(2)	(0)	(0)	(0)	
Malformation	2 (100%)		. ,		
RDIOVASCULAR SYSTEM					
Blood Vessel	(49)	(50)	(50)	(50)	

TDMS No. 88148 - 07 **Test Type:** CHRONIC

Species/Strain: MICE/B6C3F1

Route: GAVAGE

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 Test Type: CHRONIC Route: GAVAGE

Coule. GAVAGE

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene
CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Aorta, Mineralization	1 (2%)	2 (4%)		1 (2%)	
Heart	(49)	(50)	(50)	(50)	
Cardiomyopathy	3 (6%)	5 (10%)	4 (8%)	9 (18%)	
Hyperplasia, Atypical				1 (2%)	
Inflammation, Chronic Active	0 (00)	1 (2%)	. (22()	1 (2%)	
Mineralization	3 (6%)	3 (6%)	3 (6%)	2 (4%)	
Valve, Inflammation, Chronic Active		1 (2%)			
NDOCRINE SYSTEM					
Adrenal Cortex	(49)	(50)	(50)	(50)	
Accessory Adrenal Cortical Nodule	2 (4%)	2 (4%)	1 (2%)	1 (2%)	
Cyst	1 (2%)				
Degeneration, Fatty				1 (2%)	
Hematopoietic Cell Proliferation		2 (4%)	1 (2%)		
Hyperplasia	1 (2%)				
Hypertrophy	2 (4%)				
Inflammation, Chronic Active				1 (2%)	
Subcapsular, Hyperplasia	48 (98%)	50 (100%)	47 (94%)	48 (96%)	
Adrenal Medulla	(49)	(50)	(50)	(50)	
Hyperplasia	2 (4%)		2 (4%)		
Islets, Pancreatic	(49)	(50)	(50)	(50)	
Hyperplasia	1 (2%)		4>		
Parathyroid Gland	(43)	(47)	(48)	(41)	
Cyst		1 (2%)		. (00)	
Cyst, Multiple	(40)	1 (2%)	(==)	1 (2%)	
Pituitary Gland	(49)	(49)	(50)	(50)	
Pars Distalis, Angiectasis	2 (4%)	1 (2%)	3 (6%)	2 (4%)	
Pars Distalis, Cyst	2 (122()	- (100)	2 (1221)	1 (2%)	
Pars Distalis, Hyperplasia	6 (12%)	5 (10%)	8 (16%)	5 (10%)	
Thyroid Gland	(49)	(50)	(50)	(50)	
Ectopic Thymus	1 (2%)		2 (4%)		
Infiltration Cellular, Lymphoid	1 (2%)		((00)		
C-cell, Hyperplasia	4 (00()	4 (00()	1 (2%)	4 (00()	
Follicle, Cyst	1 (2%)	1 (2%)	0.4.(400()	1 (2%)	
Follicle, Degeneration	17 (35%)	28 (56%)	24 (48%)	20 (40%)	

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03 Lab: BAT

Date Report Requested: 04/24/2009

Time Report Requested: 14:57:52

Species/Strain: MICE/B6C3F1

TDMS No. 88148 - 07 **Test Type:** CHRONIC

Route: GAVAGE

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Clitoral Gland	(49)	(50)	(49)	(50)	
Atrophy	25 (51%)	44 (88%)	37 (76%)	40 (80%)	
Fibrosis	,	, ,	, ,	1 (2%)	
Infiltration Cellular, Lymphoid		5 (10%)	6 (12%)	3 (6%)	
Inflammation, Chronic Active	3 (6%)	4 (8%)	17 (35%)	25 (50%)	
Duct, Cyst	5 (10%)	46 (92%)	43 (88%)	43 (86%)	
Ovary	(49)	(50)	(50)	(50)	
Angiectasis	3 (6%)				
Atrophy	29 (59%)	44 (88%)	47 (94%)	45 (90%)	
Cyst	11 (22%)	8 (16%)	5 (10%)	4 (8%)	
Cyst, Multiple	1 (2%)				
Infiltration Cellular, Lymphoid	2 (4%)	((())			
Inflammation, Chronic Active	4 (504)	1 (2%)			
Mineralization	1 (2%)				
Pigmentation	2 (4%)	4 (00/)			
Bilateral, Cyst	(0)	1 (2%)	(4)	(0)	
Oviduct	(0)	(0)	(1)	(0)	
Inflammation, Chronic Active	(40)	(50)	1 (100%)	(50)	
Jterus	(49)	(50)	(50)	(50)	
Cyst Infiltration Cellular, Lymphoid	4 (20()	1 (2%)	1 (2%)		
	1 (2%)		4 (00()		
Inflammation, Chronic Active	45 (020()	45 (00%)	1 (2%)	41 (82%)	
Endometrium, Hyperplasia, Cystic	45 (92%)	45 (90%)	45 (90%)		
√agina Infiltration Cellular, Lymphoid	(49) 1 (2%)	(50)	(50)	(50) 1 (2%)	
Infiltration Cellular, Lymphold Infiltration Cellular, Polymorphonuclear	11 (22%)	21 (429/)	15 (30%)	18 (36%)	
Inflammation, Chronic Active	2 (4%)	21 (42%)	3 (6%)	16 (36%)	
Epithelium, Atrophy	3 (6%)	2 (4%)	3 (6%)	3 (6%)	
Epithelium, Hyperplasia	3 (0%)	1 (2%)	3 (0 %)	3 (0%)	
- Ерипенин, турегріазіа		1 (270)			
MATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Hyperplasia	2 (4%)	8 (16%)	9 (18%)	16 (32%)	
Myelofibrosis	16 (32%)	30 (60%)	33 (66%)	15 (30%)	
_ymph Node	(7)	(8)	(9)	(16)	
Bronchial, Hyperplasia, Lymphoid	1 (Ì4%)	` '	. ,	,	
Inguinal, Hyperplasia, Lymphoid	1 (14%)				
Inguinal, Pigmentation	` ,			1 (6%)	
Mediastinal, Hematopoietic Cell Proliferation		1 (13%)		,	
Mediastinal, Hyperplasia, Lymphoid		1 (13%)	2 (22%)	1 (6%)	
Mediastinal, Inflammation, Chronic Active		,	1 (11%)	,	
Mediastinal, Necrosis, Lymphoid	1 (14%)		, ,		
Mediastinal, Necrosis, Lymphold	1 (1170)				
Pancreatic, Hematopoietic Cell Proliferation Pancreatic, Hyperplasia, Lymphoid	. (1170)			1 (6%) 1 (6%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: GAVAGE

TDMS No. 88148 - 07

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Pancreatic, Pigmentation				1 (6%)	
Renal, Hyperplasia, Lymphoid				1 (6%)	
Lymph Node, Mandibular	(49)	(49)	(50)	(49)	
Hyperplasia, Lymphoid	10 (20%)	8 (16%)	9 (18%)	15 (31%)	
Necrosis, Lymphoid	1 (2%)			1 (2%)	
Pigmentation		1 (2%)	1 (2%)	2 (4%)	
Lymph Node, Mesenteric	(48)	(49)	(48)	(49)	
Hyperplasia, Lymphoid	3 (6%)		4 (8%)	2 (4%)	
Mineralization		1 (2%)			
Artery, Mineralization		1 (2%)			
Spleen	(49)	(50)	(50)	(50)	
Amyloid Deposition	` '	` '	1 (2%)	4 (8%)	
Atrophy	1 (2%)	3 (6%)	6 (12%)	3 (6%)	
Fibrosis	(/	1 (2%)	- (/	- (/	
Hematopoietic Cell Proliferation	10 (20%)	25 (50%)	21 (42%)	33 (66%)	
Hyperplasia, Lymphoid	(== 7-5)	(==,=,	1 (2%)	(5575)	
Infarct			(= 73)	1 (2%)	
Lymphoid Follicle, Hyperplasia	8 (16%)		1 (2%)	1 (2%)	
Thymus	(48)	(48)	(45)	(48)	
Atrophy	7 (15%)	15 (31%)	12 (27%)	25 (52%)	
Cyst	9 (19%)	5 (10%)	4 (9%)	3 (6%)	
Cyst, Multiple	21 (44%)	31 (65%)	33 (73%)	37 (77%)	
Ectopic Parathyroid Gland	10 (21%)	11 (23%)	20 (44%)	5 (10%)	
Ectopic Thyroid	1 (2%)	11 (23%)	20 (44 %)	3 (10%)	
Hyperplasia, Lymphoid	2 (4%)				
Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)			
Inflammation, Chronic Active		5 (10%)	12 (270/)	E (100/)	
	4 (20()		12 (27%)	5 (10%)	
Thymocyte, Necrosis	1 (2%)	1 (2%)			
NTEGUMENTARY SYSTEM					
Mammary Gland	(49)	(50)	(50)	(50)	
Skin	(49)	(50)	(50)	(50)	
Inflammation, Chronic Active		2 (4%)	6 (12%)	11 (22%)	
Dermis, Fibrosis		1 (2%)	4 (8%)	11 (22%)	
Epidermis, Hyperplasia	1 (2%)	2 (4%)	4 (8%)	11 (22%)	
Epidermis, Ulcer		1 (2%)	4 (8%)	11 (22%)	
Hair Follicle, Dilatation	2 (4%)		11 (22%)	23 (46%)	
Sebaceous Gland, Atrophy	6 (12%)	10 (20%)	11 (22%)	15 (30%)	
Subcutaneous Tissue, Inflammation, Chronic			2 (4%)		
Active			` '		
Subcutaneous Tissue, Metaplasia, Osseous			1 (2%)		

MUSCULOSKELETAL SYSTEM

3,3',4,4'-Tetrachloroazobenzene

CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

Brain	B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Skoleta Muscle	Bone	(50)	(50)	(50)	(50)	
Infilaration Cellular, Lymphoid Inflammation, Chronic Active Mineralization						
Inflammation, Chronic Active 1 (20%) 1 (13%)		(4)	(5)	(1)	(8)	
Mineralization	Infiltration Cellular, Lymphoid	1 (25%)	4 (200()			
Brain			1 (20%)		1 (13%)	
Brain						
Compression	ERVOUS SYSTEM					
Compression	Brain	(49)	(50)	(50)	(50)	
Hydrocephalus	Compression	1 (2%)	1 (2%)	` ,	,	
Meninges, Hemorrhage 1 (2%) Recrosis 2 (4%) Peripheral Nerve (0) (2) (1) (0) (2) (1) (0) (2) (1)		1 (2%)				
Neuron, Necrosis	Infiltration Cellular, Lymphoid	1 (2%)				
Peripheral Nerve (0) (2) (1) (0)	Meninges, Hemorrhage		1 (2%)			
1 (50%) Spinal Cord (0)						
Spinal Cord		(0)		(1)	(0)	
Degeneration	Sciatic, Degeneration					
Lung		(0)		(1)	(0)	
Lung (49) (50) (50) (50) (50) Hemorrhage 1 (2%) Infiltration Cellular, Lymphoid 4 (8%) 2 (4%) 2 (4%) Infiltration Cellular, Polymorphonuclear 1 (2%) Inflammation, Chronic Active 3 (6%) 5 (10%) 7 (14%) Alveolar Epithelium, Hyperplasia 1 (2%) 1 (2%) 1 (2%) 4 (8%) Alveolar Epithelium, Metaplasia, Squamous Alveolus, Infiltration Cellular, Histiocyte 3 (6%) 1 (2%) 6 (12%) Artery, Mineralization 1 (2%) Bronchiole, Metaplasia, Squamous Mediastinum, Inflammation 1 (2%) Mediastinum, Inflammation 1 (2%) Nose (50) (50) (50) (50) Inflammation, Chronic Active 4 (8%) Glands, Olfactory Epithelium, Dilatation 1 (2%) Olfactory Epithelium, Hyperplasia 1 (2%) PECIAL SENSES SYSTEM	Degeneration		1 (100%)	1 (100%)		
Mediastinum, Inflammation 1 (2%) Nose (50) (50) (50) (50) Inflammation, Chronic Active 4 (8%) Glands, Olfactory Epithelium, Dilatation Glands, Olfactory Epithelium, Hyperplasia 1 (2%) Olfactory Epithelium, Metaplasia 1 (2%) PECIAL SENSES SYSTEM	Hemorrhage Infiltration Cellular, Lymphoid Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Alveolar Epithelium, Hyperplasia Alveolar Epithelium, Metaplasia, Squamous Alveolus, Infiltration Cellular, Histiocyte Artery, Mineralization Artery, Mediastinum, Mineralization	4 (8%) 1 (2%)	2 (4%) 1 (2%) 3 (6%) 1 (2%) 3 (6%) 1 (2%)	5 (10%) 1 (2%)	1 (2%) 2 (4%) 7 (14%) 4 (8%) 1 (2%) 6 (12%)	
Inflammation, Chronic Active 4 (8%) Glands, Olfactory Epithelium, Dilatation Glands, Olfactory Epithelium, Hyperplasia 1 (2%) Olfactory Epithelium, Metaplasia 1 (2%) PECIAL SENSES SYSTEM	Mediastinum, Inflammation					
Glands, Olfactory Epithelium, Dilatation Glands, Olfactory Epithelium, Hyperplasia Olfactory Epithelium, Metaplasia 1 (2%) PECIAL SENSES SYSTEM			(50)	(50)	(50)	
Glands, Olfactory Epithelium, Hyperplasia 1 (2%) Olfactory Epithelium, Metaplasia 1 (2%) PECIAL SENSES SYSTEM		4 (8%)			0 (40()	
Olfactory Epithelium, Metaplasia 1 (2%) PECIAL SENSES SYSTEM	Glands, Olfactory Epithelium, Dilatation	4 (00()			2 (4%)	
PECIAL SENSES SYSTEM	Olfactory Epitholium, Materiasia	1 (2%)				
	Опастогу Ерипениті, метаріазіа	I (270)				
Ear (1) (0) (1) (2)	PECIAL SENSES SYSTEM					
	Ear	(1)	(0)	(1)	(2)	

TDMS No. 88148 - 07

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1

Route: GAVAGE

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC
Route: GAVAGE

TDMS No. 88148 - 07

Species/Strain: MICE/B6C3F1

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG	
Inflammation, Chronic Active	1 (100%)				
Eye	(49)	(50)	(50)	(49)	
Atrophy Cornea, Inflammation, Chronic Active	1 (2%)			1 (2%)	
Optic Nerve, Infiltration Cellular, Lymphoid			1 (2%)	1 (2%)	
Optic Nerve, Pigmentation			(=,0)	1 (2%)	
Harderian Gland	(49)	(50)	(49)	(49)	
Atrophy	1 (2%)	0 (00()	0 (40()	0 (40()	
Hyperplasia Infiltration Cellular, Lymphoid	2 (4%) 32 (65%)	3 (6%)	2 (4%) 7 (14%)	2 (4%) 4 (8%)	
Inflammation, Chronic Active	1 (2%)	13 (26%)	2 (4%)	3 (6%)	
illianimation, official Active	1 (270)		2 (470)	3 (070)	
RINARY SYSTEM					
Kidney	(49)	(50)	(50)	(50)	
Hydronephrosis			5 (10%)	3 (6%)	
Infarct	3 (6%)	6 (12%)	11 (22%)	2 (4%)	
Infiltration Cellular, Lymphoid	39 (80%)	35 (70%)	37 (74%)	26 (52%)	
Inflammation, Chronic Active		. (()		2 (4%)	
Metaplasia, Osseous	0 (400()	2 (4%)	40 (000()	4.4 (000())	
Mineralization Nephropathy	6 (12%) 29 (59%)	14 (28%) 32 (64%)	13 (26%) 38 (76%)	14 (28%) 41 (82%)	
Cortex, Cyst	1 (2%)	32 (64%)	36 (76%)	41 (62%)	
Cortex, Cyst Cortex, Cyst, Multiple	1 (2%)				
Glomerulus, Amyloid Deposition	1 (270)		1 (2%)	5 (10%)	
Papilla, Necrosis		1 (2%)	8 (16%)	2 (4%)	
Pelvis, Metaplasia, Osseous		(/	- (- · · · /	1 (2%)	
Renal Tubule, Accumulation, Hyaline Droplet	1 (2%)	2 (4%)	2 (4%)	2 (4%)	
Renal Tubule, Dilatation	1 (2%)	5 (10%)	6 (12%)	7 (14%)	
Renal Tubule, Pigmentation	1 (2%)	4.0	(=)	4-1	
Ureter	(0)	(1)	(0)	(2)	
Transitional Epithelium, Hyperplasia	(40)	(50)	(40)	1 (50%)	
Urethra Dilatation	(49)	(50)	(49) 1 (2%)	(49)	
Infiltration Cellular, Lymphoid			1 (2/0)	1 (2%)	
Inflammation, Suppurative			1 (2%)	1 (2/0)	
Transitional Epithelium, Hyperplasia		4 (8%)	(=/0)	3 (6%)	
Urinary Bladder	(49)	(50)	(50)	(50)	
Infiltration Cellular, Lymphoid	41 (84%)	30 (60%)	27 (54%)	25 (50%)	
Inflammation, Chronic Active	• •	• •	• •	2 (4%)	
Transitional Epithelium, Hyperplasia				4 (8%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88148 - 07 **Test Type:** CHRONIC

Route: GAVAGE
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3,3',4,4'-Tetrachloroazobenzene CAS Number: 14047-09-7

Date Report Requested: 04/24/2009 Time Report Requested: 14:57:52 First Dose M/F: 02/04/03 / 02/03/03

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG

*** END OF REPORT ***